Abstract:Cystic fibrosis (CF) is a single gene mutation that it is estimated to affect 30,000 children and adults in the US, and 70,000 patients worldwide. The lack of a functional gene leads to a defective ion conductance, and the associated water transport abnormalities produce increased viscosity of secretions in exocrine epithelial cells. In the respiratory airways, mucus plugging and retention produces severe lung diseases making this the main cause of mortality among CF patients. Several groups have tried to correct this defect using recombinant AAV as a vector to carry the cystic fibrosis transmembrane conductance regulator (CFTR) gene to airway epithelial cells, but without success, mostly because of poor transduction efficiency of these cells. Although AAV vectors have been used successfully in animal models, and shown efficacy in several clinical trials, a number of steps in the life cycle of AAV, including intracellular trafficking, continue to appear to limit the effectiveness of these vectors in gene therapy. We have recently documented that the substitution of surface-exposed specific tyrosine (Y), serine (S), and threonine (T) residues on AAV capsids significantly increases the transduction efficiency of these vectors, both in vitro and in vivo, presumably by preventing phosphorylation, subsequent ubiquitination, and proteasome-mediated degradation. The current studies were undertaken to identify the optimal AAV serotype vectors with improved transduction efficiency in airway epithelial cells. First, we evaluated the transduction efficiency of several commonly used AAV serotype vectors in primary normal (CRL-40111) and CF donor-derived (CRL-4013) human airway epithelial cells. Our data indicated that AAV6 serotype vectors transduce both of these cell lines at high levels, followed by AAV2, AAV5, and AAV1. Interestingly, that transduction efficiency of AAV5 vectors, but not AAV1, 2, and 6, was higher in CRL-4013 cells compared with that in CRL-4011 cells. We have previously developed a number of single- and multiple-mutant capsid-optimized vectors for each serotype (18 for AAV1, 100 for AAV2, 15 for AAV5, and 35 for AAV6). Thus, we next evaluated the transduction efficiency of these capsid-optimized AAV serotype vectors in human airway epithelial cells. The result showed that mutations in a single serine (S) residue at position 663 for AAV1, 662 for AAV2, 651 for AAV5, and 663 for AAV6 to valine (V) increased the transduction efficiency 2-3-fold compared with the wild-type (WT) AAV vectors. Among the multiple-mutants, several beneficial combinations of Y and T residues were identified, such as AAV2-Y444-500-730F+T491V, AAV1-Y705-731F+T492V, AAV5-Y263+719F and AAV6-Y705-731F+T492V, which increased the transduction efficiency 3-5-fold compared with the WT-AAV vectors. Overall, the capsid-optimized AAV6 serotype was identified as the most efficient. Studies are currently underway to generate the optimized AAV6-CFTR vector for its use in the potential gene therapy for CF.

An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia

Hepatorenal Correction in Murine Glycogen Storage Disease Type I with A Double-Stranded Adeno-Associated Virus Vector

Molecular biology and gene therapy for glycogen storage disease type Ib

Efficacy of an AAV vector encoding a thermostable form of glucocerebrosidase in alleviating symptoms in a Gaucher disease mouse model

A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a in mice with G6PC c.648G>T

Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage

Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia.

mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease

Genome editing using Staphylococcus aureus Cas9 in a canine model of glycogen storage disease Ia

Correction of glycogenosis type 2 by muscle-specific lentiviral vector

AAV-mediated expression of mouse or human GLDC normalises metabolic biomarkers in a GLDC-deficient mouse model of Non-Ketotic Hyperglycinemia

Treatment of Glutaric Aciduria Type I (GA-I) Via Intracerebroventricular Delivery of GCDH

A functional mini-GDE transgene corrects impairment in models of glycogen storage disease type III

Delivery of Glucosylceramidase Beta Gene Using AAV9 Vector Therapy As a Treatment Strategy in Mouse Models of Gaucher Disease.

315. Optimization of the Capsid of Recombinant Adeno-Associated Virus 6 (AAV6) Vectors for Liver-, and Muscle-Directed Gene Therapy

Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR‐associated protein 9–Mediated Gene Editing

Developing Gene Therapy for Mitigating Multisystemic Pathology in Fabry Disease: Proof of Concept in an Aggravated Mouse Model

Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors.

318. Development of Optimized AAV Serotype Vectors for the Potential Gene Therapy of Cystic Fibrosis

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Gene therapy for human α1-antitrypsin deficiency in an animal model using SV40-Derived vectors